Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee

[1]  W. Arend,et al.  Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. , 1993, Arthritis and rheumatism.

[2]  L. Punzi,et al.  Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. , 1993, Arthritis and rheumatism.

[3]  G. Bandara,et al.  The synovial activation of chondrocytes: evidence for complex cytokine interactions involving a possible novel factor. , 1992, Biochimica et biophysica acta.

[4]  W. Arend,et al.  IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. , 1991, Journal of immunology.

[5]  J. Pelletier,et al.  Are cytokines involved in osteoarthritic pathophysiology? , 1991, Seminars in arthritis and rheumatism.

[6]  J. Pelletier,et al.  In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage. , 1991, The Journal of rheumatology. Supplement.

[7]  M. Yaron,et al.  Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. , 1990, Arthritis and rheumatism.

[8]  B. Wilbrink,et al.  Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. , 1990, Arthritis and rheumatism.

[9]  V. Lefebvre,et al.  Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. , 1990, Biochimica et biophysica acta.

[10]  G. Turcatti,et al.  Tumor necrosis factor inhibitor: purification, NH2−terminal amino acidsequence and evidence for anti‐inflammatory and immunomodulatory activities , 1990, European journal of immunology.

[11]  P. Heinrich,et al.  Interleukin‐1β induces synthesis and secretion of interleukin‐6 in human chondrocytes , 1990, FEBS letters.

[12]  C. J. Dunn,et al.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein , 1990, Nature.

[13]  J. Hamilton,et al.  Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes , 1990 .

[14]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[15]  L. Ryd,et al.  Increased levels of proteoglycan fragments in knee joint fluid after injury. , 1989, Arthritis and rheumatism.

[16]  B. Hazleman,et al.  Transforming growth factor-beta causes partial inhibition of interleukin 1-stimulated cartilage degradation in vitro. , 1989, Biochemical and biophysical research communications.

[17]  C. Dinarello,et al.  Modulation of human chondrocyte metabolism by recombinant human interferon gamma: in-vitro effects on basal and IL-1-stimulated proteinase production, cartilage degradation and DNA synthesis. , 1989, Biochimica et biophysica acta.

[18]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[19]  E. Arner,et al.  Effect of interleukin-1-β and tumor necrosis factor-α on cartilage proteoglycan metabolismin vitro , 1989, Agents and Actions.

[20]  E. Appella,et al.  The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. , 1989, Science.

[21]  E. Arner,et al.  Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. , 1989, Arthritis and rheumatism.

[22]  P. Guerne,et al.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. , 1989, The Journal of clinical investigation.

[23]  A. Harvey,et al.  Transforming growth factor-beta is a potent inhibitor of IL-1 induced protease activity and cartilage proteoglycan degradation. , 1988, Biochemical and biophysical research communications.

[24]  I. Maurer-Fogy,et al.  A human urine-derived interleukin 1 inhibitor. Homology with deoxyribonuclease I , 1988, The Journal of experimental medicine.

[25]  A. Roberts,et al.  Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. , 1988, The Journal of biological chemistry.

[26]  C. Sledge,et al.  Effect of purified human interleukin‐1 on cartilage degradation , 1988, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[27]  R. Locksley,et al.  Tumor necrosis factors α and β differ in their capacities to generate interleukin 1 release from human endothelial cells , 1987 .

[28]  B. Mach,et al.  A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. , 1987, Journal of immunology.

[29]  P. Morrissey,et al.  Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. , 1987, Journal of immunology.

[30]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[31]  B Henderson,et al.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Hembry,et al.  Characterization of a specific antiserum to rabbit stromelysin and demonstration of the synthesis of collagenase and stromelysin by stimulated rabbit articular chondrocytes. , 1986, Collagen and related research.

[33]  J. Saklatvala.  Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage , 1986, Nature.

[34]  R. Hawkins,et al.  Followup of the acute nonoperated isolated anterior cruciate ligament tear , 1986, The American journal of sports medicine.

[35]  C. Dinarello,et al.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. , 1986, The Journal of clinical investigation.

[36]  F. Noyes,et al.  The symptomatic anterior cruciate-deficient knee. Part I: the long-term functional disability in athletically active individuals. , 1983, The Journal of bone and joint surgery. American volume.

[37]  A. Ferretti,et al.  Osteoarthritis of the knee after ACL reconstruction , 2004, International Orthopaedics.

[38]  J. Chin,et al.  Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. , 1991, Arthritis and rheumatism.

[39]  C. Evans.  The role of proteinases in cartilage destruction. , 1991, Agents and actions. Supplements.

[40]  J. Vilček,et al.  Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[41]  R. Johnson,et al.  The anterior cruciate ligament problem. , 1983, Clinical orthopaedics and related research.

[42]  F. Noyes,et al.  The symptomatic anterior cruciate deficient knee. , 1983 .